Modulation of Morphogenesis in Candida albicans by Various Small Molecules
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The pathogenic yeast Candida albicans , a member of the mucosal microbiota, is responsible for a large spectrum of infections, ranging from benign thrush and vulvovaginitis in both healthy and immunocompromised individuals to severe, life-threatening infections in immunocompromised patients. A striking feature of C. albicans is its ability to grow as budding yeast and as filamentous forms, including hyphae and pseudohyphae. The yeast-to-hypha transition contributes to the overall virulence of C. albicans and may even constitute a target for the development of antifungal drugs. Indeed, impairing morphogenesis in C. albicans has been shown to be a means to treat candidiasis. Additionally, a large number of small molecules such as farnesol, fatty acids, rapamycin, geldanamycin, histone deacetylase inhibitors, and cell cycle inhibitors have been reported to modulate the yeast-to-hypha transition in C. albicans . In this minireview, we take a look at molecules that modulate morphogenesis in this pathogenic yeast. When possible, we address experimental findings regarding their mechanisms of action and their therapeutic potential. We discuss whether or not modulating morphogenesis constitutes a strategy to treat Candida infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“albicans now ranks as the fourth leading cause of nosocomial infections and is the most common fungal species causing bloodstream infections, with associated mortality rates of 38 to 49% (62, 90, 111, 146).”
BackgroundEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“albicans now ranks as the fourth leading cause of nosocomial infections and is the most common fungal species causing bloodstream infections, with associated mortality rates of 38 to 49% (62, 90, 111, 146).”
BackgroundNonfilamentous C. albicans Mutants Are Avirulent
Lo, H.-J., Köhler, J. R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., & Fink, G. R. (1997) · Cell · doi:10.1016/s0092-8674(00)80358-x · Cited by 1,809
Antifungal agents: mechanisms of action
Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00117-3 · Cited by 1,202 · cited 1×
“These drugs exert either fungicidal or fungistatic activities by interfering with essential processes (104).”
BackgroundStructure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
Quorum Sensing in the Dimorphic Fungus Candida albicans Is Mediated by Farnesol
Hornby, J. M., Jensen, E. C., Lisec, A. D., Tasto, J. J., Jahnke, B., Shoemaker, R., Dussault, P., & Nickerson, K. W. (2001) · Applied and Environmental Microbiology · doi:10.1128/aem.67.7.2982-2992.2001 · Cited by 983
Horn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956 · cited 1×
“albicans now ranks as the fourth leading cause of nosocomial infections and is the most common fungal species causing bloodstream infections, with associated mortality rates of 38 to 49% (62, 90, 111, 146).”
BackgroundThe distinct morphogenic states of Candida albicans
Sudbery, P., Gow, N., & Berman, J. (2004) · Trends in Microbiology · doi:10.1016/j.tim.2004.05.008 · Cited by 876
Emerging opportunistic yeast infections
Miceli, M. H., Díaz, J. A., & Lee, S. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70218-8 · Cited by 811 · cited 1×
“albicans now ranks as the fourth leading cause of nosocomial infections and is the most common fungal species causing bloodstream infections, with associated mortality rates of 38 to 49% (62, 90, 111, 146).”
BackgroundNoble, S. M., French, S., Kohn, L. A., Chen, V., & Johnson, A. D. (2010) · Nature Genetics · doi:10.1038/ng.605 · Cited by 678
Saville, S. P., Lazzell, A. L., Monteagudo, C., & Lopez-Ribot, J. L. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.1053-1060.2003 · Cited by 655 · cited 2×
“Using the tet-NRG1 strain, which can be induced to filament when doxycycline is added to the drinking water of animals, studies have demonstrated that inhibiting filamentation attenuated virulence in a model of systemic candidiasis and served as an effective therapeutic intervention (120, 121).”
BackgroundA Pseudomonas aeruginosa quorum‐sensing molecule influences Candida albicans morphology
Hogan, D. A., Vik, Å., & Kolter, R. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04349.x · Cited by 575
Regulation of Cell-Surface Genes and Biofilm Formation by the C. albicans Transcription Factor Bcr1p
Nobile, C. J., & Mitchell, A. P. (2005) · Current Biology · doi:10.1016/j.cub.2005.05.047 · Cited by 464 · cited 1×
“to colonize medical devices by forming biofilms (97, 98).”
BackgroundCowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413 · cited 1×
“Nonetheless, a study has shown that harnessing Hsp90p function, either with the use of clinically relevant GdA derivatives or by genetically compromising HSP90, improved the therapeutic efficacy of an azole in two animal models of infection (31).”
BackgroundFunction of Candida albicans Adhesin Hwp1 in Biofilm Formation
Nobile, C. J., Nett, J. E., Andes, D. R., & Mitchell, A. P. (2006) · Eukaryotic Cell · doi:10.1128/ec.00194-06 · Cited by 395 · cited 1×
“to colonize medical devices by forming biofilms (97, 98).”
BackgroundEvolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375 · cited 1×
“Intensive prophylactic and therapeutic uses of antifungal agents have selected for drug-resistant strains (6, 30, 118).”
BackgroundHsp90 Orchestrates Temperature-Dependent Candida albicans Morphogenesis via Ras1-PKA Signaling
Shapiro, R. S., Uppuluri, P., Zaas, A. K., Collins, C., Senn, H., Perfect, J. R., Heitman, J., & Cowen, L. E. (2009) · Current Biology · doi:10.1016/j.cub.2009.03.017 · Cited by 311
Bamford, C. V., d'Mello, A., Nobbs, A. H., Dutton, L. C., Vickerman, M. M., & Jenkinson, H. F. (2009) · Infection and Immunity · doi:10.1128/iai.00438-09 · Cited by 291 · cited 3×
“albicans by promoting biofilm formation and invasion (11).”
BackgroundMorphogenesis and cell cycle progression in Candida albicans
Berman, J. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.10.007 · Cited by 237
Alem, M. A. S., & Douglas, L. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.41-47.2004 · Cited by 205 · cited 1×
“may account for their hypha-inhibiting activities (3, 36, 102).”
BackgroundStreptococcus mutans Competence-Stimulating Peptide Inhibits Candida albicans Hypha Formation
Jarosz, L. M., Deng, D. M., van der Mei, H. C., Crielaard, W., & Krom, B. P. (2009) · Eukaryotic Cell · doi:10.1128/ec.00070-09 · Cited by 187
The Ras/cAMP/PKA signaling pathway and virulence in Candida albicans
Hogan, D. A., & Sundstrom, P. (2009) · Future Microbiology · doi:10.2217/fmb.09.106 · Cited by 186 · cited 1×
“tially through similar mechanisms (57, 60).”
Role of Hyphal Formation in Interactions of Candida albicans with Endothelial Cells
Phan, Q. T., Belanger, P. H., & Filler, S. G. (2000) · Infection and Immunity · doi:10.1128/iai.68.6.3485-3490.2000 · Cited by 181 · cited 1×
“evade phagocytes (84), to escape from blood vessels (112), and”
BackgroundCruz, M. C., Goldstein, A. L., Blankenship, J., Del Poeta, M., Perfect, J. R., McCusker, J. H., Bennani, Y. L., Cardenas, M. E., & Heitman, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3162-3170.2001 · Cited by 159
Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy
Wurtele, H., Tsao, S., Lépine, G., Mullick, A., Tremblay, J., Drogaris, P., Lee, E.-H., Thibault, P., Verreault, A., & Raymond, M. (2010) · Nature Medicine · doi:10.1038/nm.2175 · Cited by 157
Evolution of Drug Resistance in Candida Albicans
Cowen, L. E., Anderson, J. B., & Kohn, L. M. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160907 · Cited by 151
Smith, W. L., & Edlind, T. D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3532-3539.2002 · Cited by 147 · cited 2×
“Moreover, several HDAC inhibitors have been shown to modulate hyphal development and virulence (55, 129, 131, 148).”
BackgroundEnjalbert, B., & Whiteway, M. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.7.1203-1210.2005 · Cited by 145 · cited 1×
“albicans to farnesol, global gene expression analyses were performed (21, 25, 38, 119).”
MethodHnisz, D., Majer, O., Frohner, I. E., Komnenovic, V., & Kuchler, K. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000889 · Cited by 124 · cited 5×
“ment promoted hyphal development under noninducing conditions (55).”
BackgroundInfluentialToenjes, K. A., Munsee, S. M., Ibrahim, A. S., Jeffrey, R., Edwards, J. E., & Johnson, D. I. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.963-972.2005 · Cited by 72
ODDS, F. C., COCKAYNE, A., HAYWARD, J., & ABBOTT, A. B. (1985) · Microbiology · doi:10.1099/00221287-131-10-2581 · Cited by 67
Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans
Simonetti, G., Passariello, C., Rotili, D., Mai, A., Garaci, E., & Palamara, A. T. (2007) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2007.00276.x · Cited by 57
Cited by
Growth of Candida albicans hyphae
Sudbery, P. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2636 · Cited by 1,110
Thymol, thyme, and other plant sources: Health and potential uses
Salehi, B., Mishra, A. P., Shukla, I., Sharifi‐Rad, M., Contreras, M. D. M., Segura‐Carretero, A., Fathi, H., Nasrabadi, N. N., Kobarfard, F., & Sharifi‐Rad, J. (2018) · Phytotherapy Research · doi:10.1002/ptr.6109 · Cited by 551
Oral Candidiasis: A Disease of Opportunity
Vila, T., Sultan, A. S., Montelongo-Jauregui, D., & Jabra-Rizk, M. A. (2020) · Journal of Fungi · doi:10.3390/jof6010015 · Cited by 537
Candida albicans dimorphism as a therapeutic target
Jacobsen, I. D., Wilson, D., Wächtler, B., Brunke, S., Naglik, J. R., & Hube, B. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.152 · Cited by 363
Targeting Candida albicans filamentation for antifungal drug development
Vila, T., Romo, J. A., Pierce, C. G., McHardy, S. F., Saville, S. P., & Lopez-Ribot, J. L. (2017) · Virulence · doi:10.1080/21505594.2016.1197444 · Cited by 174
Metadata
- Authors
- Shareck, J., & Belhumeur, P.
- Venue
- Eukaryotic Cell
- Publisher
- American Society for Microbiology
- Published
- 2011-08
- Volume
- 10
- Issue
- 8
- Pages
- 1004-1012
- ISSN
- 1535-9778 (ISSN-L)
- 1535-9786
- OpenAlex
- W2169494061
- Cited by
- 142
- References
- 33
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.